Search / Trial NCT00001418

PET Scan in Patients With Neurocardiologic Disorders

Launched by NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE (NINDS) · Nov 3, 1999

Trial Information

Current as of October 18, 2024

Completed

Keywords

Sympathetic Nervous System Dysautonomias Postural Tachycardia Syndrome Neurocardiogenic Syncope Hypernoradrenergic Hypertension Sympathectomy Fluorodopamine Positron Emission Tomography Norepinephrine Dopamine Neurocardiologic Disorder

Description

This project applies positron emission tomographic (PET) scanning after administration of 6-\[18F\]fluorodopamine (\[18F\]-6F-DA) to visualize sympathetic innervation and function in patients with neurocardiologic disorders. Patients undergo infusion of \[18F\]-6F-DA, followed by PET scanning of one or more body regions. Patients may also undergo PET scanning after administration of \[13N\]-ammonia, to assess regional perfusion; regional blood sampling (including sampling from the coronary sinus or great cardiac vein) during infusion of \[3H\]-l-norepinephrine (\[3H\]-NE), to assess the kin...

Gender

ALL

Eligibility criteria

  • INCLUSION CRITERIA:
  • The subjects are adult patients in one of the following diagnostic categories: coronary heart disease or chest pain and normal coronary arteries; myocardial dysfunction or failure; hypertension; or dysautonomia. Groups of appropriately matched healthy volunteers are studied concurrently as controls.
  • EXCLUSION CRITERIA:
  • Minors are excluded.
  • Subjects in whom anatomic factors complicate vascular access are excluded.
  • Subjects who are not expected clinically to tolerate recumbency during the procedures are excluded.
  • Pregnant or lactating women are excluded.
  • Cardiology patients may be tested while off their usual medications. In this situation, the patients will be inpatients on the cardiology ward, managed clinically by staff of the Cardiology Branch, DIR, NHLBI. Hypertensives will be tested afer having discontinued anti-hypertensive medications for up to two weeks.
  • Patients who must take medications continually in the following categories are excluded: anticoagulants, tricyclic antidepressants, barbiturates, aspirin, acetaminophen.
  • Patients unable to discontinue nicotine or alcohol temporarily are excluded.

About National Institute Of Neurological Disorders And Stroke (Ninds)

The National Institute of Neurological Disorders and Stroke (NINDS) is a leading component of the National Institutes of Health (NIH), dedicated to advancing our understanding of the brain and nervous system through innovative research. NINDS sponsors and conducts clinical trials aimed at developing effective treatments and improving patient outcomes for a wide range of neurological disorders, including stroke, epilepsy, multiple sclerosis, and neurodegenerative diseases. By fostering collaboration among researchers, healthcare providers, and patient communities, NINDS plays a pivotal role in transforming scientific discoveries into clinical applications, ultimately enhancing the quality of life for individuals affected by neurological conditions.

Locations

Bethesda, Maryland, United States

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0